| 1.62 Data as of 1:18pm ET |  +0.01 / +0.62%Today’s Change | 1.20 Today|||52-Week Range 2.95 | +21.80% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $72.3M |
Company Description
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. Its pipeline includes products from two primary families of compounds: Protectans, which are being developed as drug candidates that protect normal tissues from acute stresses, such as radiation, chemotherapy and ischemias; and Curaxins, which are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. The company was founded by Andrei V. Gudkov on June 5, 2003 and is headquartered in Buffalo, NY.
Employees
Shareholders
| Mutual fund holders | 2.33% |
| Individual stakeholders | 14.44% |
| Other institutional | 10.28% |
Top Executives
| Michael Fonstein, PhD | President & Director |
| Yakov Kogan, PhD, MBA | Chief Executive Officer, COO & Director |
| C. Neil Lyons, CPA | CFO, Head-Investor & Public Relations |
| Andrei V. Gudkov, PhD | Director & Chief Scientific Officer |
| Michael R. Kurman, MD | Chief Medical Officer |
.
